Vivos Therapeutics (VVOS) Income towards Parent Company (2020 - 2026)
Vivos Therapeutics (VVOS) reported Income towards Parent Company of -$7.8 million for Q1 2026, down 100.6% year-over-year from $1.3 billion in Q1 2025, and down 11.46% quarter-over-quarter from -$7.0 million in Q4 2025.
Vivos Therapeutics (VVOS) Income towards Parent Company (2020 - 2026) Analysis & Trends
Vivos Therapeutics (VVOS) has 7 years of Income towards Parent Company data on file, last reported at -$7.8 million in Q1 2026.
- Income towards Parent Company for Q1 2026 came in at -$7.8 million, down 100.6% year-over-year; the trailing twelve-month figure through Mar 2026 was -$25.1 million (down 122.38% YoY), and the FY2025 annual result was -$21.2 million, down 89.66% from the prior year.
- Income towards Parent Company declined to -$7.8 million in Q1 2026 per VVOS's latest filing, from -$7.0 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at $9.4 million in Q4 2023 and troughed at -$7.8 million in Q1 2026.
- A 5-year average of -$3.8 million and a median of -$5.0 million in 2025 frame the typical range for Income towards Parent Company.
- The sharpest annual moves came in 2023 and 2025: Income towards Parent Company surged 253.83% in 2023, then slumped 159.74% in 2025.
- A 5-year view of Income towards Parent Company shows it stood at -$6.1 million in 2022, then surged by 253.83% to $9.4 million in 2023, then tumbled by 130.8% to -$2.9 million in 2024, then sank by 141.04% to -$7.0 million in 2025, then declined by 11.46% to -$7.8 million in 2026.
- Business Quant data shows VVOS's Income towards Parent Company at -$7.8 million in Q1 2026, -$7.0 million in Q4 2025, and -$5.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 157.80 Bn | 151.14 Bn | 6.27 Bn |
| 2 | Stryker | 115.54 Bn | 112.66 Bn | 3.81 Bn |
| 3 | Medtronic | 103.44 Bn | 95.27 Bn | 5.76 Bn |
| 4 | Boston Scientific | 72.38 Bn | 71.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 49.76 Bn | 46.09 Bn | 1.29 Bn |
| 6 | Dexcom | 29.53 Bn | 28.42 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 29.51 Bn | 27.44 Bn | 1.98 Bn |
| 8 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 9 | Steris | 20.69 Bn | 20.27 Bn | 697.10 Mn |
| 10 | Vivos Therapeutics | 12.96 Mn | 10.73 Mn | 3.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.75 Mn |
| Dec 31, 2025 | -6.95 Mn |
| Sep 30, 2025 | -5.40 Mn |
| Jun 30, 2025 | -5.01 Mn |
| Mar 31, 2025 | -3.86 Mn |
| Dec 31, 2024 | -2.89 Mn |
| Sep 30, 2024 | -2.62 Mn |
| Jun 30, 2024 | -1.93 Mn |
| Mar 31, 2024 | -3.76 Mn |
| Dec 31, 2023 | 9.37 Mn |
| Sep 30, 2023 | -2.09 Mn |
| Jun 30, 2023 | -5.53 Mn |
| Mar 31, 2023 | -1.70 Mn |
| Dec 31, 2022 | -6.09 Mn |
| Sep 30, 2022 | -5.43 Mn |
| Jun 30, 2022 | -6.99 Mn |
| Mar 31, 2022 | -5.33 Mn |
| Dec 31, 2021 | -7.41 Mn |
| Sep 30, 2021 | -5.45 Mn |
| Jun 30, 2021 | -4.04 Mn |